Josh Bartch

Novel psychedelic-based drugs biotech Mydecine Innovations Group, Inc. (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA) completed its admission to Access segment of the UK’s stock market, AQSE Growth Market. Trading started on Tuesday under ticker MYIG. “We are incredibly...

Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications. This is the first step in the process of receiving a patent, which needs to be granted by an overseeing body. Mydecine's Patent On The MYCO-006 Family Of Compounds...

Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product.  Mydecine focuses on developing first and second-generation novel therapeutics for the treatment of...

Mydecine Innovations Group (NEO: MYCO) (OTCPINK: MYCOF), a biotech company in the psychedelics space, announced on Wednesday the launch of a virtual drug discovery program that will use artificial intelligence and machine learning to inform its drug discovery process. “The in-silico...

MAPS Gets $30M In Funds To Conclude MDMA Research The Multidisciplinary Association for Psychedelic Studies recently completed a fundraising of $30 million. The funds will help MAPS finish the NGO’s ongoing research for MDMA-assisted psychotherapy in the treatment of post-...

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) announced Wednesday that it has begun to exercise its GMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin. The psilocybin is naturally derived from whole-mushroom extraction...

NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) reported Tuesday it has completed its 7,500 square-feet lab in Denver, Colorado. The newly built mycology-centered research and development lab is first of its type in the country, the company said in a press release. It will be managed by...